AS

Akiko Suzuki

Senior Medical Director at Iovance Biotherapeutics

Akiko Suzuki has an extensive work experience in the medical field. Akiko currently holds the position of Senior Medical Director at Iovance Biotherapeutics, Inc. since January 2022. Prior to this, they worked as a Senior Medical Director at AstraZeneca from August 2019 to August 2021. Akiko also served as a Medical Director at The Janssen Pharmaceutical Companies of Johnson & Johnson from September 2017 to July 2019. Before transitioning into industry roles, they gained experience as a Research Associate at the FDA from May 2015 to August 2017 and as a Postdoctoral fellow from October 2009 to April 2015. Akiko's earlier career included working as a Remote Radiologist at Doctor-NET Inc. from November 2013 to July 2017 and as an Assistant Professor at Yokohama City University from April 2006 to September 2009. Akiko also served as a Radiologist at affiliate hospitals in Yokohama, Japan, from April 2002 to March 2006 and as an Internal Medicine Resident at Asahi General Hospital from April 2000 to March 2002.

Akiko Suzuki pursued their education in the field of medicine. Akiko completed their Doctor of Medicine (MD) degree from Gunma University Faculty of Medicine, attending from 1994 to 2000. Subsequently, they furthered their studies at Yokohama City University, where they obtained a Doctor of Philosophy (Ph.D.) degree in Radiology from 2002 to 2006.

To enhance their expertise, Akiko Suzuki also sought additional certifications. In 2011, they completed the Translational Research in Clinical Oncology Course from the National Cancer Institute (NCI). In the same year, they also completed the Demystifying Medicine Course offered by the National Institutes of Health.

Furthermore, Akiko Suzuki holds the Japanese Board of Radiology Certification, although information regarding the institution or the specific timing of this certification is not provided.

Links

Previous companies

AstraZeneca logo

Timeline

  • Senior Medical Director

    January, 2022 - present

View in org chart